RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
60 hedge funds and large institutions have $31M invested in RVL Pharmaceuticals plc Ordinary Shares in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 22 reducing their positions, and 9 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 22
3% less funds holding
Funds holding: 62 → 60 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
31% less capital invested
Capital invested by funds: $45.1M → $31M (-$14.1M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$5.63M |
| 2 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
+$1.28M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$782K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$193K |
| 5 |
Renaissance Technologies
New York
|
+$167K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DG Capital Management
New York
|
-$5.74M |
| 2 |
CCM
CAAS Capital Management
New York
|
-$2.62M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1.1M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$819K |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$668K |
RVLP Hedge Fund Activity: Q4 2020 in Review
60 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q4 2020, worth a combined $31M — down 31% from $45.1M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of RVLP and 7 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 22 added.
The largest buyer was Morgan Stanley, adding an estimated $5.63M. The largest seller was DG Capital Management, cutting an estimated $5.74M.
- 60 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q4 2020, down from 62 in Q3 2020.
- Funds reported $31M of RVL Pharmaceuticals plc Ordinary Shares stock for Q4 2020, down 31% quarter-over-quarter.
- 7 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q4 2020 and 9 closed out, a net change of -2 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q4 2020 was Morgan Stanley, an estimated $5.63M added.
- The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q4 2020 was DG Capital Management, an estimated $5.74M sold.
Based on aggregated 13F filings for Q4 2020.